Manuscripts
The following information for Canadian Healthcare Professionals includes links to Apellis-sponsored clinical trials that have been published in peer reviewed journals. The list of publications below may contain information about doses, uses, formulations and populations different from product labeling or contain information about investigational compounds or uses not approved by a regulatory authority. The following list of publications is not comprehensive or exhaustive as to any particular topic. Apellis does not suggest or recommend the use of its products in any manner other than as described in the Product Monograph. Please refer to the product’s full Product Monograph.
Select a disease area
By expanding you’re confirming that your query is unsolicited.
Geographic Atrophy (GA)
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
- Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402(10411):1434-1448. doi:10.1016/S0140-6736(23)01520-9.
- Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise
- Singh R, Amoaku W, Bandello F, et al. Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise. Ophthalmic Surg Lasers Imaging Retina 2023;54:589–598 doi: 10.3928/23258160-20230824-01.
- Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review
- Sarda, Sujata & Heyes, Anne & Bektas, Meryem & Thakur, Tanvee & Chao, Wendy & Intorcia, Michele & Wronski, Samantha & Jones, Daniel. (2021). Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review. Clinical ophthalmology (Auckland, N.Z.). 2021. 4629–4644. 10.2147/OPTH.S338253.
- Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy
- Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021;128(9):1325-1336. doi:10.1016/j.ophtha.2021.02.025.
- Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study
- Liao DS, Metlapally R, Joshi P. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study. Immunotherapy. 2022;14:13, 995-1006. doi:10.2217/imt-2022-0078.
- Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan
- Steinle NC, Pearce I, Monés J, et al. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan. Am J Ophthalmol. 2021;227:116-124. doi:10.1016/j.ajo.2021.02.031.
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
- Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020;127(2):186-195. doi:10.1016/j.ophtha.2019.07.011